230 related articles for article (PubMed ID: 16734726)
1. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
2. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
6. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
[TBL] [Abstract][Full Text] [Related]
12. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
13. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
15. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.
Fu HL; Ma Y; Lu LG; Hou P; Li BJ; Jin WL; Cui DX
J Biomed Nanotechnol; 2014 Jul; 10(7):1217-30. PubMed ID: 24804542
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
[TBL] [Abstract][Full Text] [Related]
18. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
